Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

威罗菲尼 医学 安慰剂 内科学 人口 黑色素瘤 癌症研究 转移性黑色素瘤 肿瘤科 病理 癌症 环境卫生 替代医学
作者
Paolo A. Ascierto,Grant A. McArthur,Brigitte Dréno,Victoria Atkinson,Gabrielle Liszkay,Anna Maria Di Giacomo,Mario Mandalà,Lev Demidov,Daniil Stroyakovskiy,L. Thomas,Luís de la Cruz-Merino,Caroline Dutriaux,Claus Garbe,Yibing Yan,Matthew Wongchenko,Ilsung Chang,Jessie J. Hsu,Daniel O. Koralek,Isabelle Rooney,Antoni Ribas
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:17 (9): 1248-1260 被引量:929
标识
DOI:10.1016/s1470-2045(16)30122-x
摘要

The combination of cobimetinib with vemurafenib improves progression-free survival compared with placebo and vemurafenib in previously untreated patients with BRAF(V600)-mutant advanced melanoma, as previously reported in the coBRIM study. In this Article, we report updated efficacy results, including overall survival and safety after longer follow-up, and selected biomarker correlative studies.In this double-blind, randomised, placebo-controlled, multicentre study, adult patients (aged ≥18 years) with histologically confirmed BRAF(V600) mutation-positive unresectable stage IIIC or stage IV melanoma were randomly assigned (1:1) using an interactive response system to receive cobimetinib (60 mg once daily for 21 days followed by a 7-day rest period in each 28-day cycle) or placebo, in combination with oral vemurafenib (960 mg twice daily). Progression-free and overall survival were primary and secondary endpoints, respectively; all analyses were done on the intention-to-treat population. This study is registered with ClinicalTrials.gov, number NCT01689519, and is ongoing but no longer recruiting participants.Between Jan 8, 2013, and Jan 31, 2014, 495 eligible adult patients were enrolled and randomly assigned to the cobimetinib plus vemurafenib group (n=247) or placebo plus vemurafenib group (n=248). At a median follow-up of 14·2 months (IQR 8·5-17·3), the updated investigator-assessed median progression-free survival was 12·3 months (95% CI 9·5-13·4) for cobimetinib and vemurafenib versus 7·2 months (5·6-7·5) for placebo and vemurafenib (HR 0·58 [95% CI 0·46-0·72], p<0·0001). The final analysis for overall survival occurred when 255 (52%) patients had died (Aug 28, 2015). Median overall survival was 22·3 months (95% CI 20·3-not estimable) for cobimetinib and vemurafenib versus 17·4 months (95% CI 15·0-19·8) for placebo and vemurafenib (HR 0·70, 95% CI 0·55-0·90; p=0·005). The safety profile for cobimetinib and vemurafenib was tolerable and manageable, and no new safety signals were observed with longer follow-up. The most common grade 3-4 adverse events occurring at a higher frequency in patients in the cobimetinib and vemurafenib group compared with the vemurafenib group were γ-glutamyl transferase increase (36 [15%] in the cobimetinib and vemurafenib group vs 25 [10%] in the placebo and vemurafenib group), blood creatine phosphokinase increase (30 [12%] vs one [<1%]), and alanine transaminase increase (28 [11%] vs 15 [6%]). Serious adverse events occurred in 92 patients (37%) in the cobimetinib and vemurafenib group and 69 patients (28%) in the vemurafenib group. Pyrexia (six patients [2%]) and dehydration (five patients [2%]) were the most common serious adverse events reported in the cobimetinib and vemurafenib group. A total of 259 patients have died: 117 (47%) in the cobimetinib and vemurafenib group and 142 (58%) in the vemurafenib group. The primary cause of death was disease progression in most patients: 109 (93%) of 117 in the cobimetinib and vemurafenib group and 133 (94%) of 142 in the vemurafenib group.These data confirm the clinical benefit of cobimetinib combined with vemurafenib and support the use of the combination as a standard first-line approach to improve survival in patients with advanced BRAF(V600)-mutant melanoma.F Hoffmann-La Roche-Genentech.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
大个应助山丘采纳,获得10
1秒前
lulubeans完成签到,获得积分10
2秒前
rock发布了新的文献求助10
2秒前
张磊完成签到,获得积分10
2秒前
liuguohua126完成签到,获得积分10
2秒前
琪七发布了新的文献求助10
2秒前
2秒前
625关注了科研通微信公众号
2秒前
方芳芳完成签到,获得积分10
2秒前
2秒前
水木飞雪完成签到,获得积分10
3秒前
封皮人完成签到,获得积分10
3秒前
4秒前
LQ关注了科研通微信公众号
4秒前
kecheng应助汪汪队路马采纳,获得10
5秒前
szh123发布了新的文献求助10
5秒前
5秒前
gj2221423完成签到 ,获得积分10
5秒前
不安的未来完成签到,获得积分10
5秒前
自由山槐发布了新的文献求助10
6秒前
zyy发布了新的文献求助10
6秒前
smottom应助大马哈鱼采纳,获得20
6秒前
千幻发布了新的文献求助10
6秒前
领导范儿应助lqkcqmu采纳,获得30
7秒前
windyTE完成签到,获得积分10
7秒前
SYLH应助负责的雨柏采纳,获得10
8秒前
9秒前
大个应助tt采纳,获得10
10秒前
Yoh1220发布了新的文献求助30
10秒前
12秒前
知画春秋完成签到,获得积分10
12秒前
13秒前
13秒前
14秒前
大气石头完成签到,获得积分10
15秒前
李健应助开心夏真采纳,获得10
15秒前
15秒前
JJ完成签到,获得积分10
16秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3970572
求助须知:如何正确求助?哪些是违规求助? 3515219
关于积分的说明 11177438
捐赠科研通 3250374
什么是DOI,文献DOI怎么找? 1795265
邀请新用户注册赠送积分活动 875750
科研通“疑难数据库(出版商)”最低求助积分说明 805054